The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A pilot study of PLX3397, a selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor, in pigmented villonodular synovitis (PVNS).
William D. Tap
Consultant or Advisory Role - Plexxikon
Research Funding - Plexxikon
Stephen Patrick Anthony
Research Funding - Plexxikon
Bartosz Chmielowski
Consultant or Advisory Role - Bristol-Myers Squibb; CytRx Corporation; Genentech; GlaxoSmithKline
Honoraria - Bristol-Myers Squibb; Genentech; Prometheus
Research Funding - Plexxikon
Arthur P. Staddon
Research Funding - Plexxikon
Allen Lee Cohn
Research Funding - Plexxikon
Geoffrey Shapiro
Research Funding - Plexxikon
Igor Puzanov
Consultant or Advisory Role - Daiichi Sankyo
Research Funding - Plexxikon
Eunice L Kwak
Research Funding - Plexxikon
Andrew J Wagner
Consultant or Advisory Role - Novartis; Plexxikon
Research Funding - Plexxikon
Charles Peterfy
Employment or Leadership Position - Spire Sciences, Inc.
Stock Ownership - Spire Sciences, Inc.
Henry H Hsu
Consultant or Advisory Role - Plexxikon
Carolyn Gee
Consultant or Advisory Role - Plexxikon
Paul S. Lin
Employment or Leadership Position - Plexxikon
Sandra Tong
Employment or Leadership Position - Plexxikon
Zev A. Wainberg
Research Funding - Plexxikon